documented protocols
Fosgonimeton: what is documented about dosing
The trial dose arms are on the public record. They belong to an investigational drug given by injection under supervision, and they are not a protocol for anything else.
- Primary sources Registry records and papers are read at the source, not through summaries. Read the methodology
- Every claim graded Each claim about what a compound does carries an evidence tier and a numbered citation. How grades derive
- Sells nothing No cart, no price, and no product page anywhere on this site. Conflict disclosure
- Corrections logged Errors are fixed and recorded in a permanent public log, never edited away. Corrections log
What follows is what the registered trials administered. This compound is not sold as a research chemical and this page is a record of a clinical programme.
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
What this page reports, and what it does not
We report what has been documented. We do not prescribe what should be done.
Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.
No trial established an amount of Fosgonimeton for a person. Most of the rows below record what a published study gave to its animals or its cells, in the model that study built, with the species and the route named on the line. One row records that other figures circulate in community write-ups, and that this site does not republish them. Nothing here is a protocol, nothing here is scaled for a person, and this site publishes no preparation steps, no administration technique and no equipment. The reasoning is in the editorial policy.
Commonly cited protocols (extrapolated, not validated)
| Study | What was given | Frequency | Duration | Notes |
|---|---|---|---|---|
| LIFT-AD, NCT04488419 | Two dose arms against placebo, reported on the hub | Not restated here | 26 weeks to the primary endpoint | 554 participants. Subcutaneous injection. The primary analysis compared placebo with the lower of the two arms |
| NCT04886063 | Open-label extension dosing | As per the extension protocol | Terminated before completion | 423 participants. Results posted |
| NCT03298672 | Phase 1 dose escalation | As per protocol | Short-term | 88 participants. No posted results |
| NCT05511558 | Single dose for absorption, metabolism and excretion | Single dose | Single dose | 8 participants. No posted results |
The figures above describe an investigational medicine given by subcutaneous injection to people with a diagnosis, in a hospital-supervised trial, with monitoring and withdrawal criteria attached. They are a record of what a protocol specified.
Commonly cited protocols (extrapolated, not validated) do not exist for this compound in the way they do for the research chemicals elsewhere in this catalogue, because it is not sold that way. Where a figure from these trials appears attached to a different compound sold on the same mechanism, it has been moved from one molecule to another and it does not carry across.
Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.
Our takeReal dose arms exist here and they describe a clinical trial rather than a practice. The pivotal trial that used them did not meet its primary endpoint.,Talk to a licensed clinician about anything concerning your health.
Main routes people compare
Subcutaneous injection
The route used throughout the clinical programme. The compound is a prodrug converted in the body after administration.
What is said about cycle length and timing
The pivotal trial ran to a primary endpoint at 26 weeks, with an open-label extension that was terminated after the parent trial's result. No other duration appears in the registered record.
Talk to a licensed clinician about anything concerning your health.
What has been measured about safety
A reader weighing what other people report giving usually wants the other half of the record next. What has been measured about Fosgonimeton, and what has never been studied reports what has actually been measured, in what system and over what period, and the questions no published study has put.
Frequently asked questions
What doses were used in the trials?
The Phase 2/3 used 40 mg and 70 mg arms against placebo, given by subcutaneous injection daily, with the primary endpoint at 26 weeks. The pre-specified primary analysis compared placebo with the 40 mg arm.
Can those figures be applied to a compound sold on the same mechanism?
No. They belong to this molecule, given by injection as a prodrug, in a supervised trial. Moving a figure from one molecule to another is not supported by anything published.
Is fosgonimeton available to buy?
This site is not aware of it being sold. It is an investigational drug that has not been approved in any indication.
References
- LeonaBio. ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD). Phase 2/3, 554 participants, completed 15 July 2024. Results posted. Primary outcome the Global Statistical Test score at week 26; primary analysis population placebo or 40 mg, modified intention-to-treat, restricted to participants not taking acetylcholinesterase inhibitors. Posted least-squares means: placebo -0.126 (SE 0.0683, n=144), ATH-1017 40 mg -0.208 (SE 0.0707, n=143). No analysis or p-value posted for the primary outcome. Read through the v2 API on 23 August 2026. ClinicalTrials.gov. 2020. NCT04488419
- LeonaBio. Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease. Phase 2/3, 423 participants, terminated, completed 23 October 2024. Results posted. The registry's whyStopped field reads: ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score. ClinicalTrials.gov. 2021. NCT04886063
- LeonaBio. A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease. Phase 2, 77 participants, completed. No posted results. ClinicalTrials.gov. 2020. NCT04491006
- LeonaBio. Safety, Tolerability, and Pharmacokinetics Study of ATH-1017. Phase 1, 88 participants, completed. No posted results. ClinicalTrials.gov. 2017. NCT03298672
- LeonaBio. ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial). Phase 2, 28 participants, terminated, completed 19 April 2023. The registry's whyStopped field reads: Enrollment ended early due to study design limitations. ClinicalTrials.gov. 2021. NCT04831281
- LeonaBio. A Study of the Absorption, Metabolism, and Excretion of ATH-1017. Phase 1, 8 participants, completed. No posted results. ClinicalTrials.gov. 2022. NCT05511558
- ClinicalTrials.gov. Registry sweep for fosgonimeton, ATH-1017, NDX-1017 and fosgonimeton acetate across the intervention and free-text fields, run through the v2 API on 23 August 2026. Six distinct records returned, all of them this compound. ClinicalTrials.gov. 2026. ClinicalTrials.gov
- Wright JW, Harding JW. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2015. PMID 25649658
- Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. 2015. PMID 25455861
- Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neurosci Biobehav Rev. 2018. PMID 29733881
- Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014. PMID 25187433 DOI 10.1124/jpet.114.218735 Retracted April 2025. Cited here only to identify the mechanism literature shared with the research chemical sold on this target, and not as evidence.
- Siller R, Greenhough S, Naumovska E, Sullivan GJ. Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Reports. 2015. PMID 25937370